HYPERLIPIDEMIA AND CARDIOVASCULAR DISEASE: Edited by Paul N. DurringtonSmall interfering RNA to proprotein convertase subtilisin/kexin type 9: transforming LDL-cholesterol-lowering strategiesBrandts, Juliaa,b; Ray, Kausik K.bAuthor Information aDepartment of Medicine I, University Hospital RWTH Aachen, Aachen, Germany bImperial Centre for Cardiovascular Disease Prevention, School of Public Health, Imperial College London, London, UK Correspondence to Kausik K. Ray, FRCP, Primary Care and Public Health, Imperial College London, 320 Reynolds Building, Dunstan Road, London W68RP, UK. Tel: +44 0 20 7594 0716; e-mail: email@example.com Current Opinion in Lipidology: August 2020 - Volume 31 - Issue 4 - p 182-186 doi: 10.1097/MOL.0000000000000691 Buy Metrics Abstract Purpose of review Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition is a new strategy to reduce LDL cholesterol (LDL-C), that is currently pursued by mAbs. A promising novel approach to target PCSK9 is using small interfering RNAs to inhibit hepatic PCSK9 synthesis. The first small interfering RNA developed for this purpose is inclisiran. Here, we review its clinical trial data and potential impact on patient management. Recent findings Inclisiran achieves sustained, additional 50% LDL-C reduction in patients receiving background statin therapy. Resulting LDL-C changes can be maintained by an infrequent dosing regimen with twice per year injections, that appear safe and well tolerated. Thus far, inclisiran has been studied in patients with established cardiovascular disease, high-risk primary prevention and in patients with familial hypercholesterolemia. Summary High and very high-risk individuals may benefit from the additional LDL-C-lowering effect of inclisiran when added to current lipid-lowering therapies. Furthermore, the simple dosing regimen may improve the convenience for users and facilitate patient adherence to therapy. The safety and convenience of inclisiran may offer new opportunities for population health. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.